Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Condition:   Breast Cancer Interventions:   Drug: TOL2506;   Drug: Tamoxifen;   Drug: Letrozole tablets;   Drug: Anastrozole Tablets;   Drug: Exemestane Tablets Sponsor:   Tolmar Inc. Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials